169. Eur J Cancer. 2018 May;94:126-137. doi: 10.1016/j.ejca.2018.02.005. Epub 2018 Mar20.Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparingtwo strategies for guiding prevention with enalapril: The InternationalCardioOncology Society-one trial.Cardinale D(1), Ciceri F(2), Latini R(3), Franzosi MG(4), Sandri MT(5), CivelliM(6), Cucchi G(7), Menatti E(8), Mangiavacchi M(9), Cavina R(10), Barbieri E(11),Gori S(12), Colombo A(1), Curigliano G(13), Salvatici M(5), Rizzo A(14), Ghisoni F(15), Bianchi A(16), Falci C(17), Aquilina M(18), Rocca A(19), Monopoli A(20),Milandri C(21), Rossetti G(22), Bregni M(23), Sicuro M(24), Malossi A(25),Nassiacos D(26), Verusio C(27), Giordano M(28), Staszewsky L(4), Barlera S(4),Nicolis EB(4), Magnoli M(4), Masson S(4), Cipolla CM(6); ICOS-ONE StudyInvestigators.Collaborators: Cipolla CM, Cardinale D, Ciceri F, Latini R, Sandri MT, MaggioniAP, Labianca R, Tettamanti M, Senni M, Finzi A, Grosso F, Vago T, Civelli M,Gramenzi S, Masson S, Balconi G, Bernasconi R, Salvatici M, Nicolis E, Barlera S,Magnoli M, Buratti MG, Ojeda Fernandez ML, Franzosi MG, Staszewsky L, Vasamì A,Malossi A, Sicuro M, Thiebat B, Barè C, Corzani A, Coccolo F, Colecchia S,Pellegrini C, Bregni M, Appio L, Caico I, G Rossetti, Mesenzani O, Campana C,Giordano M, Gilardoni M, Scognamiglio G, Corrado G, Battagin D, De Rosa F,Carpino C, Palazzo S, Monopoli A, Milandri C, Giannessi PG, Zipoli G, Ghisoni F, Rizzo A, Pastori P, Callegari S, Sesenna C, Colombo A, G Curigliano, Fodor C,Mangiavacchi M, Cavina R, Guiducci D, Mazza R, Turazza FM, Vallerio P, MarbelloL, Sala E, Fragasso G, Trinca S, Aquilina M, Rocca A, Farolfi A, Andreis D, Gori S, Barbieri E, Lanzoni L, Marchetti F, Falci C, Bianchi A, Mioranza E, Banzato A,Re F, Gaibazzi N, Gullo M, Turina MC, Gervasi E, Giaroli F, Nassiacos D, Verusio C, Barco B, Bertolini A, Cucchi G, Menatti E, Sinagra G, Aleksova A, Guglielmi A,Pinotti G, Gueli R, Mongiardi C, Vallini I.Author information: (1)Cardioncology Unit, European Institute of Oncology, Milano, Italy.(2)Haematology/Transplant Unit, Istituto Scientifico H. San Raffaele, Milano,Italy.(3)Department of Cardiovascular Research, IRCCS - Mario Negri Institute forPharmacological Research, Milano, Italy. Electronic address:roberto.latini@marionegri.it.(4)Department of Cardiovascular Research, IRCCS - Mario Negri Institute forPharmacological Research, Milano, Italy.(5)Laboratory Medicine Division, European Institute of Oncology, Milano, Italy.(6)Cardioncology Division, European Institute of Oncology, Milano, Italy.(7)Cardiology, Ospedale di Sondrio, Italy.(8)Oncology, Ospedale di Sondrio, Italy.(9)Cardiology, Istituto Clinico Humanitas, Rozzano, Italy.(10)Oncology, Istituto Clinico Humanitas, Rozzano, Italy.(11)Cardiology, Ospedale Sacro Cuore, Negrar, Italy.(12)Oncology, Ospedale Sacro Cuore, Negrar, Italy.(13)Division of Early Drug Development for Innovative Therapy, Department ofOncology and Hemato-Oncology, University of Milano, European Institute ofOncology, Milano, Italy.(14)Cardiology, Ospedale di Vaio, Fidenza, Italy.(15)Unità Operativa Complessa Cure Palliative, Ospedale di Vaio, Fidenza, Italy.(16)Cardiology, Istituto Oncologico Veneto, Padova, Italy.(17)Oncology, Istituto Oncologico Veneto, Padova, Italy.(18)Cardiology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori- IRCCS, Meldola, Italy.(19)Oncology, IRCCS-Istituto Scientifico Romagnolo per lo Studio e la Cura deiTumori, Meldola, Italy.(20)Cardiology, Nuovo Ospedale San Giuseppe, Empoli, Italy.(21)Oncology, Nuovo Ospedale San Giuseppe, Empoli, Italy.(22)Cardiology, Presidio Ospedaliero di Busto Arsizio, Italy.(23)Oncology, Presidio Ospedaliero di Busto Arsizio, Italy.(24)Cardiology, Ospedale Regionale Umberto Parini, Aosta, Italy.(25)Oncology, Ospedale Regionale Umberto Parini, Aosta, Italy.(26)Cardiology, Presidio Ospedaliero di Saronno, Saronno, Italy.(27)Oncology, Presidio Ospedaliero di Saronno, Saronno, Italy.(28)Oncology, Azienda Socio Sanitaria Territoriale Lariana, Como, Italy.BACKGROUND: Troponin changes over time have been suggested to allow for an early diagnosis of cardiac injury ensuing cancer chemotherapy; cancer patients withtroponin elevation may benefit of therapy with enalapril. It is unknown whether apreventive treatment with enalapril may further increase the benefit.METHODS: The International CardioOncology Society-one trial (ICOS-ONE) was acontrolled, open-label trial conducted in 21 Italian hospitals. Patients wererandomly assigned to two strategies: enalapril in all patients started beforechemotherapy (CT; 'prevention' arm), and enalapril started only in patients with an increase in troponin during or after CT ('troponin-triggered' arm). Troponinwas assayed locally in 2596 blood samples, before and after eachanthracycline-containing CT cycle and at each study visit; electrocardiogram and echocardiogram were done at baseline, and at 1, 3, 6 and 12-month follow-up.Primary outcome was the incidence of troponin elevation above the threshold.FINDINGS: Of the 273 patients, 88% were women, mean age 51 ± 12 years. Themajority (76%) had breast cancer, 3% had a history of hypertension and 4% werediabetic. Epirubicin and doxorubicin were most commonly prescribed, with mediancumulative doses of 360 [270-360] and 240 [240-240] mg/m2, respectively. Theincidence of troponin elevation was 23% in the prevention and 26% in thetroponin-triggered group (p = 0.50). Three patients (1.1%) -two in theprevention, one in the troponin-triggered group-developed cardiotoxicity, definedas 10% point reduction of LV ejection fraction, with values lower than 50%.INTERPRETATION: Low cumulative doses of anthracyclines in adult patients with lowcardiovascular risk can raise troponins, without differences between the twostrategies of giving enalapril. Considering a benefit of enalapril in theprevention of LV dysfunction, a troponin-triggered strategy may be moreconvenient.Copyright © 2018 Elsevier Ltd. All rights reserved.DOI: 10.1016/j.ejca.2018.02.005 PMID: 29567630 